Optic Nerve Disorders Treatment Market to Witness Robust Growth Due To Increasing Prevalence of Eye Disorders

 

Optic Nerve Disorders Treatment Market

Optic nerve disorder is a rare autoimmune disease that indicates degeneration of the optic nerve. There are many types of optic nerve disorders, such as optic nerve atrophy, optic neuritis, and glaucoma. An individual with glaucoma can use eye drops, take oral medications, or undergo eye surgery such as laser therapy. Antibiotics such as tetracycline, isoniazid, and ethambutol cause optic neuritis. In some cases, steroid-based medications are used to reduce inflammation in the optic nerve. However, once damaged, the optic nerve cannot be repaired since the damage is irreversible. The optic nerve disorders treatment market is expected to witness robust growth due to increasing prevalence of the disease.

Glaucoma is the second most common cause of blindness globally. According to the Glaucoma Research Foundation (GRF), a national non-profit organization, by 2040, around 1,118 million people worldwide will have glaucoma. According to the World Health Organization (WHO), there are several types of glaucoma, however, the two most common are, primary open angle glaucoma (POAG) and angle closure glaucoma (ACG). More than 90% of cases of glaucoma remain undiagnosed in the community. Thus, with the increasing prevalence, the demand for optic nerve disorders treatment is also increasing.

For instance, in August 2020, The U.S. Food and Drug Administration (USFDA) approved Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optic spectrum disorder in adults with a particular antibody. Enspryng is the third approved treatment for the disorder. Moreover, in June 2020, FDA approved Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optic spectrum disorder in adult patients with a particular antibody. Uplizna is the second approved treatment for the disorder. Therefore, increasing drug approvals by USFDA for treatment of optic nerve disorders are expected to drive growth of the optic nerve disorders treatment market.

Moreover, growth of the optic nerve disorders treatment market is driven by the increasing prevalence of eye disorders worldwide, especially in North America. According to the Centers for Disease Control and Prevention (CDC), around 12 million Americans, aged 40 years and over, have vision impairment. Thus, demand for optic nerve disorders treatment is increasing with the increasing prevalence of eye disorders. For instance, in February 2021, Viela Bio reported updated safety, efficacy, and long-term use results of UPLIZNA (inebilizumab-cdon), including interim data from the open-label extension period of the pivotal N-MOmentum trial in patients with neuromyelitis optic spectrum disorder.

However, side effects associated with steroid drugs and optic nerve disorder drugs are expected to restrain the optic nerve disorders treatment market growth.

Comments

Popular posts from this blog

Bourbon Whiskey Is the Most Popular Whiskey in America and In Many Other Countries around the World

Viral Vectors And Plasmid DNA Manufacturing Market Is Gaining Major Traction With Oxford Biomedica Plc Entering Into A 3-Year Agreement With Boehringer Ingelheim For The Manufacture And Supply Of Various Types Of Viral Vectors

Hard Surface Flooring Market Is Expected To Witness Robust Growth As Mohawk Industries Introduces Newly Imagined 30,000-Square Foot Floor Space At The International Surface Event (TISE)